Stifel Reiterates Buy Rating on Enliven Therapeutics
Stifel maintains its buy rating on Enliven Therapeutics with a price target of $80, a 57.64% upside from the current price.
Key Points
- Stifel reiterated its buy rating on Enliven Therapeutics, setting a price target of $80.
- Stifel's $80 price target implies 57.64% upside from Enliven Therapeutics, Inc.'s ($ELVN) current $50.75 share price.
- Shares of NasdaqGS:ELVN traded near $50.75 on Wednesday, with a market cap of about $3.63 billion.
- Institutional investors like Polar Capital Holdings increased their stake by 44.2% to 5,065,933 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Stifel has reiterated its buy rating on Enliven Therapeutics, Inc. (NasdaqGS:ELVN), maintaining a price target of $80. This update came on July 1, 2026, as shares of Enliven traded around $50.75.
Stifel vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Analysts Set New Price Targets
On July 1, 2026, Stifel maintained its buy rating on Enliven Therapeutics with a price target of $80. This follows a series of positive ratings; on June 29, 2026, Jones Trading also maintained a buy rating with a $70 target. Earlier, on June 9, 2026, Stifel initiated coverage with a buy rating and a $60 target.
Other Institutional Activity in Enliven Therapeutics
Several institutional investors have been active in Enliven Therapeutics. Polar Capital Holdings PLC increased its holdings by 1,552,253 shares, ending with 5,065,933 shares worth about $198.6 million, a 44.2% increase. Meanwhile, FMR LLC reduced its position by 278,389 shares to hold 6,829,246 shares valued at approximately $267.7 million, a 3.9% decrease. Commodore Capital LP cut its stake by 1,417,809 shares, ending with 3,275,000 shares worth $128.4 million, a 30.2% reduction.
Enliven Therapeutics, Inc. Stock Down 12.3%
Shares of Enliven Therapeutics traded near $50.75 on Wednesday. The company, with a market cap of about $3.63 billion, operates in the biotechnology sector. It has a beta of 0.396, indicating lower volatility compared to the market. The stock has seen a 52-week low of $14.79 and a high of $52.39, with moving averages of $42.22 (50-day) and $29.09 (200-day). Enliven has a strong current ratio of 40.318 and a quick ratio of 39.384, reflecting robust liquidity.
$ELVN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Enliven Therapeutics, Inc.
Recent insider transactions include OrbiMed Advisors LLC selling 860,123 shares on June 22, 2026. On June 17, 2026, CFO Benjamin Hohl sold 6,018 shares at an average price of $43.80 under a pre-planned 10b5-1 trading plan. Additionally, Chief Medical Officer Helen Louise Collins bought 5,000 shares at $2.48 and sold the same amount at $43.80 on the same day.
About Enliven Therapeutics
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boulder, Colorado. Founded in 2019, it focuses on developing small molecule inhibitors for cancer treatment. The company is advancing its clinical programs, including ELVN-001 for chronic myeloid leukemia and ELVN-002 for non-small cell lung cancer.
Bottom Line
Stifel's reiteration of a buy rating with an $80 price target underscores continued confidence in Enliven Therapeutics' potential. Enliven's stock performance and institutional activity highlight its position in the biotech sector. Investors should note that these analyst opinions reflect past data and market conditions.
Get Enliven Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ELVN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.